Company Performance Metrics
Lexicon Bio develops a small-molecule platform for precise transcriptional editing in human cells. The company focuses on ScripTACs, bifunctional small molecules that couple a target-binding module with an effector module to recruit endogenous proteins and modulate gene expression. Its platform combines modular chemistry for rapid library synthesis
with high-throughput, transcriptome-scale profiling to characterize on- and off-target biology. These capabilities are used to build libraries of transcriptional editors and to link chemical structure directly to transcriptional signatures. Lexicon Bio applies this approach to therapeutic programs in oncology, regenerative medicine and immunology, including indications such as metastatic castration-resistant prostate cancer, heart failure with reduced ejection fraction, and inflammatory bowel diseases.
